



The evidence is stacked in its favour

**Established efficacy in both
hypertension and angina**

**A reliable choice for good
tolerability in both young and
elderly patients¹**

**More consistent compliance
than nifedipine retard²**

TM

AMLODIPINE

ABBREVIATED PRESCRIBING INFORMATION FOR ISTIN™ (AMLODIPINE): UK.

PRESENTATION: TABLETS CONTAINING 5MG OR 10MG AMLODIPINE. **INDICATIONS:** FIRST-LINE TREATMENT OF HYPERTENSION AND MYOCARDIAL ISCHAEMIA ASSOCIATED WITH STABLE ANGINA PECTORIS OR VASOSPASTIC (PRINZMETAL'S OR VARIANT) ANGINA. **DOSAGE:** FOR HYPERTENSION AND ANGINA, INITIAL DOSAGE 5MG ORALLY ONCE DAILY WHICH MAY BE INCREASED TO A MAXIMUM DAILY DOSAGE OF 10MG. **USE IN CHILDREN:** NOT RECOMMENDED. **USE IN THE ELDERLY:** NORMAL DOSAGE. **USE IN RENAL IMPAIRMENT:** NORMAL DOSAGE. **USE IN HEPATIC IMPAIRMENT:** DOSAGE RECOMMENDATIONS HAVE NOT BEEN ESTABLISHED; USE WITH CAUTION. **CONTRA-INDICATIONS:** KNOWN SENSITIVITY TO DIHYDROPYRIDINES. **WARNINGS AND PRECAUTIONS:** PREGNANCY AND LACTATION: ISTIN SHOULD NOT BE ADMINISTERED DURING PREGNANCY OR LACTATION, OR TO WOMEN OF CHILD-BEARING POTENTIAL UNLESS EFFECTIVE CONTRACEPTION IS USED. **SIDE-EFFECTS:** OEDEMA, HEADACHE, FLUSHING, DIZZINESS, NAUSEA, PALPITATIONS, FATIGUE, ABDOMINAL PAIN AND SOMNOLENCE. LESS COMMONLY, PRURITUS, DYSPNOEA, ASTHENIA, MUSCLE CRAMPS, DYSPEPSIA AND GINGIVAL HYPERPLASIA. RASH, AND RARELY ERYTHEMA MULTIFORME HAVE BEEN OBSERVED. AS WITH OTHER CALCIUM CHANNEL BLOCKERS, THE FOLLOWING, WHICH CANNOT BE DISTINGUISHED FROM THE NATURAL HISTORY OF THE UNDERLYING DISEASE HAVE BEEN RARELY REPORTED: MYOCARDIAL INFARCTION AND CHEST PAIN. **FURTHER INFORMATION:** STUDIES HAVE SHOWN THAT ISTIN DID NOT LEAD TO CLINICAL DETERIORATION IN NYHA



CLASS II-III HEART FAILURE. STUDIES HAVE NOT BEEN PERFORMED IN PATIENTS WITH CLASS IV HEART FAILURE. **LEGAL CATEGORY:** POM. **PACKAGE QUANTITIES AND BASIC NHS COST:** 5MG TABLETS CALENDAR PACK OF 28 £11.85 (PL 0057/0297); 10MG TABLETS CALENDAR PACK OF 28 £17.70 (PL 0057/0298). FURTHER INFORMATION ON REQUEST. **PFIZER LIMITED,** RAMSGATE ROAD, SANDWICH, KENT CT13 9NJ. **REFERENCES:** 1. CROSS BW ET AL. BR J CLIN PRAC, 1993, 47(5): 237-240. 2. DETRY JR. CLIN CARDIOL, 1994, 17 (SUPPL III): 12-16.

Abbreviated Prescribing Information

Presentation: Ampoules containing dalteparin sodium 10,000 IU (anti-Factor Xa) in 1ml. No preservative present. **Indication:** Unstable coronary artery disease, defined as newly developed or increased angina or ongoing chest pain, with the electrocardiogram changes of non Q-wave myocardial infarction. **Dosage:** Adults and elderly. 120 IU/kg bodyweight subcutaneously twelve-hourly. The maximum dose is 10,000 IU/12 hours. The recommended treatment period is 5-8 days. Concomitant therapy with low-dose aspirin is recommended. **Contraindications:** Known hypersensitivity to Fragmin; acute gastroduodenal ulcer; cerebral haemorrhage; known haemorrhagic diathesis; subacute endocarditis; injuries to and operations on the central nervous system, eyes and ears; thrombocytopenia in patients with a positive result in the *in-vitro* aggregation test in the presence of dalteparin sodium. **Precautions:** Do not administer by the intramuscular route. Caution should be exercised in patients in whom there is an increased risk of bleeding complications, e.g. following surgery or trauma, haemorrhagic stroke, severe liver failure, thrombocytopenia or defective platelet function, uncontrolled hypertension, hypertensive or diabetic retinopathy, patients receiving concurrent anticoagulant / antiplatelet agents, and also patients with known hypersensitivity to heparin and/or to other low molecular weight heparins. Patients with severely disturbed hepatic function may need a reduction in dosage and should be monitored accordingly. Fragmin induces only a moderate prolongation of the APTT and thrombin time. Accordingly, dosage increments based upon prolongation of the APTT may cause overdosage and bleeding. Therefore, prolongation of the APTT should only be used as a test of overdosage. If a transmural myocardial infarction occurs in patients with unstable coronary artery disease, thrombolytic treatment might be appropriate. This does not necessitate discontinuation of treatment with Fragmin, but might increase the risk of bleeding. This medicinal product has been assessed in pregnant women and no harmful effects are known with respect to the course of pregnancy and the health of the unborn and neonate. No information is available as to whether Fragmin passes into breast milk. **Side-effects:** Bleeding may be provoked, especially at high dosages corresponding with anti-Factor Xa levels greater than 1.5 IU/ml. However, at recommended dosages bleeding rarely occurs. Transient, slight to moderate elevation of liver transaminases (ASAT, ALAT) has been observed, but no clinical significance has been demonstrated. Commonly reported side-effects include subcutaneous haematomas at the injection site. Thrombocytopenia and allergic reactions (urticaria, pruritus, hair loss and skin necrosis) occur rarely. Few cases of anaphylactoid reactions have been observed. Osteoporosis has been associated with long-term heparin treatment and therefore cannot be excluded with Fragmin. **Overdose:** 100 IU Fragmin is inhibited by 1mg protamine; see Summary of Product Characteristics for full prescribing information. **Legal category:** POM. **Packs:** Fragmin 10,000 IU/1ml ampoule, basic NHS price of £53.63 per pack of ten ampoules. **PL Number:** 10,000 IU/1ml 0022/0075. Further information is available on request: Pharmacia & Upjohn Limited, Davy Avenue, Milton Keynes, MK5 8PH. Tel: 01908 661101. Fax: 01908 690091. Date of preparation: March 1997.


Reference:

1. FRISC Study Group. Lancet 1996; 347: 561-568.



**Pharmacia
& Upjohn**

Further information is available on request
from: Pharmacia & Upjohn Limited,
Davy Avenue, Milton Keynes MK5 8PH.
Tel: 01908 661101. Fax: 01908 690091.
Date of preparation: March 1997. Ref: P2807



Adds convenience to your control of unstable coronary artery disease

- ◆ Fragmin is a new advance in cardiology: a convenient regimen for the control of unstable coronary artery disease — delivered by a simple s.c. injection.
- ◆ Fragmin avoids the cost and complexity of i.v. standard heparin, and does not require monitoring.
- ◆ Fragmin has reduced death and MI in UCAD by up to 63% ($p=0.001$) when added to a standard regimen.¹

Twice-daily injectable

Fragmin[®]
dalteparin sodium



The world's first LMWH in cardiology



syscor[®] MR
nisoldipine

acts selectively
on the coronary
arteries

Syscor MR (nisoldipine) is a new, once-daily Ca^{2+} antagonist with different pharmacological properties to other Ca^{2+} antagonists^{1,2}.

Because nisoldipine acts selectively on the coronary arteries compared with the myocardium and peripheral vessels^{2,3}, there is no clinical negative inotropic effect⁴, and "... no change in heart rate occurred with nisoldipine coat-core" (Syscor MR) in the DEFIANT I study⁵. Syscor MR also has a very low incidence of acute peripheral vasodilator side-effects⁶.

Syscor MR, Bayer's 3rd generation Ca^{2+} antagonist, is an effective once-daily therapy in chronic stable angina and mild to moderate hypertension.

SYSCOR[®] MR 10, 20, 30 - ABRIDGED PRESCRIBING INFORMATION ▼ Refer to full Summary of Product Characteristics before prescribing. **Qualitative and quantitative composition:** Film-coated tablets each containing 10 mg, 20 mg, or 30 mg nisoldipine. **Pharmaceutical form:** Modified (extended) release tablets for oral administration. **Therapeutic indications:** Mild to moderate arterial essential hypertension. Prophylaxis of chronic stable angina pectoris. **Posology and method of administration:** Syscor MR tablets must be swallowed whole; under no circumstances should they be bitten, chewed or broken up. Taken once daily, swallowed whole with a little liquid at approximately 24-hour intervals, i.e. at the same time each day, preferably during the morning. A food interaction has been observed, and it is therefore preferable to administer Syscor MR in the fasting state, i.e. before breakfast. The recommended initial dose in angina pectoris is 10 mg once-daily. The usual maintenance dose is 20-40 mg once-daily. The maximum recommended dose is 40 mg once-daily. In hypertension, the recommended initial dose is one 10 mg tablet once-daily. If necessary, the dosage can be increased according to individual requirements up to a maximum of 40 mg once-daily. Assess at least one week after starting on any dosage before titration to a higher dosage. Renal impairment: Dosage adjustment should not be necessary. Elderly: Therapy should commence with 10 mg once-daily, with titration to higher doses if clinically warranted and according to tolerability. Treatment may be continued indefinitely. **Contra-indications:** Known hypersensitivity to nisoldipine or other dihydropyridines; children aged less than 12 years; pregnant women or nursing mothers; cardiogenic shock;

unstable angina or during or within one month of myocardial infarction; secondary prevention of myocardial infarction; acute angina attacks; malignant hypertension; fixed cardiac output obstruction, such as aortic stenosis; hepatic impairment. **Special warnings and special precautions for use:** Caution in patients with hypertension as there is a risk of further reduction in blood pressure. **Interactions with other medicaments and other forms of interaction:** If used in combination with beta-blocking drugs, a possible additive effect resulting in bradycardia should be borne in mind. Syscor MR may not prevent possible rebound effects after cessation of other antihypertensive therapy. No significant interaction of Syscor MR and propranolol, but a possible additive effect of the two drugs must be borne in mind. Interactions have been observed with cimetidine, nitroglycerin, quinidine and grapefruit juice. Possibility of interaction with phenytoin or carbamazepine cannot be excluded. No interaction has been observed with ranitidine, warfarin or digoxin. **Effect on ability to drive and use machines:** None known. **Undesirable effects:** Gradual facial oedema; headache; flushing; tachycardia; palpitation; dizziness and gastrointestinal disorders such as nausea and constipation; less frequently: paraesthesia; hypotension; asthma; dyspnoea and allergic skin reactions (rash, itching); exacerbation of angina pectoris at the start of treatment. The occurrence of myocardial infarction was not distinguishable from the natural course of ischaemic heart disease. Disturbances of the enzymes AST, SGOT, ALT, SGPT and CPK may occur which tend to return to normal with continuation of therapy. If abnormalities do not regress within a few weeks, discontinue treatment. Enzyme elevations usually regress

on discontinuation of the drug. Syscor MR has a mild hypotensive effect. Increased diuresis has been observed in isolated cases. **Legal category:** POM. **Package quantities and basic NHS costs:** Calendar packs containing 28 tablets. Syscor MR 10 £9.80. Syscor MR 20 £13.72. Syscor MR 30 £17.64. **Marketing Authorisation numbers:** PL 0010/0198/0200. **Date of Preparation:** March 1997.

REFERENCES 1. Kado S et al. *Arzneim-Forsch Drug Res* 1996; 30 (III): 2144-2162. 2. Godfrand T et al. *J Cardiovasc Pharmacol* 1992; 20 (Suppl 5): S34-S41. 3. Schmitt M et al. In: Hugenholz RG, Meyer J, eds. *Nisoldipine 1987*. Berlin: Heidelberg: Springer-Verlag, 1987; 109-114. 4. Schmitt M et al. *J Cardiovasc Pharmacol* 1992; 20 (Suppl 5): S79-S81. 5. DEFIANT I Research Group. *Eur Heart J* 1993; 13: 1496-1505. 6. Lewis BS. *Am J Cardiol* 1995; 75: 46E-53E.

Further information available from:


Bayer plc, Pharmaceutical Division, Bayer House, Strawberry Hill, Newbury, Berkshire RG14 1JA. Telephone: (01635) 563000. 1. Registered trademark of Bayer AG, Germany. 2. Bayer plc, March 1997. Bayer and BAYEN are trademarks of Bayer AG, Germany.

Bayer
BAYEN

FOR ALL KINDS OF PATIENTS



highly effective antihypertensive therapy **80mg**



Heaven Can Wait



ZOCOR® (simvastatin, MSD)

ABRIDGED PRODUCT INFORMATION

Refer to Summary of Product Characteristics before prescribing

PRESENTATION

Peach, oval-shaped, film-coated tablets, marked 'ZOCOR 10' on one side, containing 10 mg simvastatin, MSD.
Tan, oval-shaped, film-coated tablets, marked 'ZOCOR 20' on one side, containing 20 mg simvastatin, MSD.
Brick-red, oval-shaped, film-coated tablets, marked 'MSD 749' on one side, containing 40 mg simvastatin, MSD.

INDICATIONS

- Primary hypercholesterolaemia unresponsive to diet and other non-pharmacological measures.
- In patients with coronary heart disease and a plasma cholesterol level of 5.5 mmol/l or greater, to
 - reduce risk of mortality
 - reduce risk of coronary death and non-fatal myocardial infarction
 - reduce risk for undergoing myocardial revascularising procedures (CABG and PTCA)
 - slow the progression of coronary atherosclerosis, including reducing development of new lesions and new total occlusions.

DOSAGE AND ADMINISTRATION

Hypercholesterolaemia: Initially 10 mg *nocte*; dose range 10–40 mg once daily *nocte*.

Maximum therapeutic response occurs within four to six weeks. Consider dose reduction if total serum cholesterol level falls below 3.6 mmol/l or if LDL cholesterol falls below 1.94 mmol/l. (See Data Sheet for full dosage instructions.) A standard cholesterol-lowering diet should be continued.

Coronary heart disease

Starting dose 20 mg day *nocte*. Adjustment of dose as above.

Concomitant therapy: 'Zocor' is effective alone or in combination with bile-acid sequestrants. In patients taking immunosuppressants concomitantly with 'Zocor', the maximum recommended dosage is 10 mg day (see below).

Impaired renal function: In patients with severe renal insufficiency (creatinine clearance < 30 ml/min), dosages above 10 mg day should be carefully considered and, if deemed necessary, implemented cautiously.

Elderly patients: Modification of dose should not be necessary.

Children: Studies to show safety and efficacy have not been done.

CONTRA-INDICATIONS

Hypersensitivity to this product; active liver disease or unexplained persistent elevations of serum transaminases; porphyria; pregnancy and breast-feeding; women of childbearing potential unless adequately protected by non-hormonal methods.

PRECAUTIONS

Homozygous familial hypercholesterolaemia: 'Zocor' is unlikely to be effective.
Hypertriglyceridaemia: 'Zocor' is not indicated where hypertriglyceridaemia is the abnormality of most concern.

Hepatic effects: Initial and periodic liver-function monitoring recommended. Discontinue if persistent enzyme elevations occur, particularly if they rise to three times the upper limit of normal. Caution in patients with a history of liver disease and/or alcoholism.

Muscle effects: Clinically insignificant transient mild elevations of creatine phosphokinase have been seen. Therapy with HMG-CoA reductase inhibitors has rarely been associated with myopathy (< 0.1%). Myopathy should be considered in any patient with marked elevations of creatine phosphokinase (CPK) levels (≥ 10 times the upper limit of normal) or with diffuse myalgias, muscle tenderness and such marked elevations of CPK levels. The patient should be asked to report promptly unexplained muscle pain, tenderness or weakness.

The risk of myopathy with HMG-CoA reductase inhibitors is known to be increased by concomitant immunosuppressive therapy including cyclosporine, by concomitant therapy with a fibric acid derivative or lipid-lowering doses of nicotinic acid, and believed to be enhanced by itraconazole. There have been rare reports of severe rhabdomyolysis with secondary acute renal failure. Therefore, the benefits and risks of using simvastatin concomitantly with immunosuppressive or fibrate drugs, lipid-lowering doses of nicotinic acid or itraconazole and other systemic azole antifungal derivatives should be carefully considered.



Pregnancy: Contra-indicated. One month should elapse between ending therapy with 'Zocor' and planned conception.

Paediatric use: Safety and effectiveness in children have not been established.
Drug interactions: Care should be taken in patients on concomitant lipid-lowering therapy, particularly fibrates or nicotinic acid derivatives or itraconazole or immunosuppressive therapies, as they are at increased risk of myopathy.

In two clinical studies, 'Zocor' modestly potentiated the anticoagulant effect of warfarin; patients taking coumarin derivatives should have their prothrombin time determined prior to therapy with 'Zocor' and monitored as usual. Slight elevation in digoxin levels has been seen when co-administered with 'Zocor'.

SIDE EFFECTS

Side effects reported most frequently in controlled clinical trials: abdominal pain, constipation, flatulence, asthenia, and headache. Rarely, myopathy.

Side effects reported either in long-term extension studies or in marketed use: nausea, diarrhoea, rash, dyspepsia, pruritus, alopecia, dizziness, muscle cramps, myalgia, pancreatitis, paraesthesia, peripheral neuropathy, vomiting, and anaemia. Rarely, rhabdomyolysis and hepatitis jaundice occurred. An apparent hypersensitivity syndrome has been reported rarely which has included some of the following features: angioedema, lupus-like syndrome, polymyalgia rheumatica, vasculitis, thrombocytopenia, eosinophilia, ESR increased, arthritis, arthralgia, urticaria, photosensitivity, fever, flushing, dyspnoea, and malaise. Marked and persistent increased serum transaminases have been reported infrequently. Elevated alkaline phosphatase and γ -glutamyl transpeptidase have

been reported. Liver-function test abnormalities have generally been mild and transient. Increases in CPK (muscle derived) have been reported.

Side effects reported but where a causal relationship to 'Zocor' is not established: depression, erythema multiforme including Stevens-Johnson syndrome, leucopenia, and purpura.

PACKAGE QUANTITIES AND BASIC NHS COST

10 mg tablets, £18.29 for 28-tablet calendar pack
20 mg tablets, £31.09 for 28-tablet calendar pack
40 mg tablets, £47.04 for 28-tablet calendar pack

Product licence numbers:

10 mg tablets, 0025 0241
20 mg tablets, 0025 0242
40 mg tablets, 0025 0243

Product licence holder:

Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU

POM Date of review: January 1997.

* denotes registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.
© Merck Sharp & Dohme Limited 1996. All rights reserved.

Reference

1. Scandinavian Simvastatin Survival Study Group. *Lancet*, 1994, 344, 1383.

ZOCOR®

(simvastatin, MSD)

The only statin proven to save the lives of post-MI and angina patients*



MSD


Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU

1-98 ZCR.96.GB.70826.J. D

Introducing the CrossFlex Stent

**Specially designed to access
side branches, distal lesions,
and small, tortuous vessels.**

The low-profile, balloon-expandable CrossFlex employs an extremely flexible stainless steel, helical coil structure that provides excellent trackability and conformability. For side branches, distal lesions, and those small, tortuous vessels, it makes an ideal choice.



- Extremely flexible
- Sheathless low profile
- Consistent sizing through repeat inflations
- Optimal 15% metal-to-artery ratio
- Over-the-wire and rapid exchange delivery systems

To learn more about this helpful and highly specialized new interventional tool, contact your Cordis representative.

Cordis Corporation
14740 N.W. 60th Avenue
Miami Lakes, Florida 33014
USA
1 (800) 327-7714

Cordis Latin America
6303 Blue Lagoon Drive
Suite 450
Miami, Florida 33126
USA
(305) 261-3500

Cordis Canada
2630 Lancaster Road, Unit I
Ottawa, Ontario K1B 5L8
Canada
(613) 739-4545
in Canada: 1 (800) 465-8989

Cordis Neich, Ltd.
25th Floor, Cindic Tower
128 Gloucester Road
Hong Kong
(852) 2802-2288

**Johnson & Johnson
Medical NV/SA**
Waterloo Office Park
Drève Richelle 161-H
B-1410 Waterloo, Belgium
(322)-352-1411

Cordis Japan Corporation
Shinjuku Square Tower 14F
6-22-1 Nishi-shinjuku,
Shinjuku-ku
Tokyo 163-11, Japan
81-3-5323-4341

Medtronic.Kappa™ pacing systems.

Better for your patient. Easier for you.

*Not only have we improved pacing therapy,
we've also made it less complicated. Introducing
Medtronic.Kappa 400 Series pacing systems.*

Medtronic.Kappa systems let you focus on the

patient, as the system initiates

therapy and automatically

ensures patient-specific heart

rate management from implant forward. It also

validates therapy with automatic diagnostic

tools. But that's only part of the story.

Medtronic.Kappa pacing systems are also easier for you and those around you.


The system handles the detail, while you oversee the appropriate therapy. It's

easier to learn and to use, faster to implant and to follow-up. So you have more

time for patients. Medtronic.Kappa 400 Series pacing systems. Better for your

patient, easier for you. It's that simple. Just ask your Medtronic representative.

Medtronic Arrhythmia Management. Restoring Rhythms, Renewing Lives.



Medtronic 

Medtronic Europe S.A.
World Trade Center
2, Avenue Gratta Paille
C.P. 468
1000 Lausanne 30 Grey
Switzerland
Telephone: (41-21) 641 5200
FAX (41-21) 641 5252

Medtronic of Canada Ltd.
6733 Kitimat Road
Mississauga, Ontario L5N 1W3
Canada
Telephone: (905) 826-6020
FAX (905) 826-6620
Toll-free: 1-800-268-5346
(24-hour consultation service)

© Medtronic, Inc. 1997

Once daily

Tildie.

Prescribing Information: Tildiem LA200 and LA300 capsules containing 200mg or 300mg diltiazem HCL in a mixture of immediate release and sustained release pellets. **Indications:** Angina pectoris and mild to moderate hypertension. **Dosage and Administration:** Elderly and patients with impaired hepatic or renal function: Angina and hypertension: The initial dose should be one Tildiem LA200 capsule daily. This dose may be increased to one capsule of

Tildiem LA300 daily if clinically indicated. Heart rate should be monitored and if it falls below 50 beats per minute the dose should not be increased. Plasma levels of diltiazem can be increased in this group of patients. **Adults:** Angina and hypertension: The usual starting dose is Tildiem LA300 once daily. This dose may be increased to 2 capsules of Tildiem LA200 daily, and if clinically indicated a higher dose of one Tildiem LA200 plus one Tildiem LA300 capsule may

be considered. **Children:** Tildiem LA should not be prescribed. The capsules should not be chewed swallowed whole with water, ideally before or during a meal. When changing from one type of Tildiem formulation to another it may be necessary to adjust the dosage until a satisfactory response is obtained. **Contraindications:** Pregnancy, women of child-bearing potential, marked bradycardia, sick sinus syndrome, left ventricular failure.



diltiazem HCl 200 & 300

stasis, second or third degree AV block in the absence of a functioning pacemaker, concomitant use with dantrolene infusion. **Warnings and Precautions:** Caution in patients with reduced ventricular function, mild bradycardia, first degree AV block or prolonged PR interval. Concomitant use with drugs known to induce bradycardia or hypotension. **Side-effects:** Lower limb oedema, headache, hot flushes/flushing, asthenia/fatigue, palpitations, malaise,

minor GI disorders and skin rash have been described. **Basic NHS Costs:** Tildiem LA200 28 capsules £11.61. Tildiem LA300 28 capsules £12.80. **Legal Category:** POM **Product Licence Numbers:** Tildiem LA200 4969/0016. Tildiem LA300 4969/0014. **Product Licence Holder:** Lorex Synthélabo Ltd, Lunar House, Globe Park, Marlow, Bucks, SL7 1LW. Date of preparation: April 1997. Code No: TIL301 AD97. Tildiem and Lorex Synthélabo are trade marks.



Lorex Synthélabo

**It's easy to be the leader
in cardiac imaging.
We just follow you.**



Listening to cardiologists puts us way ahead in meeting your clinical and economic needs. That's why more cath labs use Philips X-ray equipment than any other kind. Why hospitals are improving productivity with "swing labs" and CD-Medical digital archiving. And why we're working with leading research institutions to develop practical MR cardiac perfusion and coronary artery imaging.

Why are we always looking ahead?
Because you are.


Let's make things better.



PHILIPS


NEW LIPITOR

STRENGTH



to reduce cholesterol and triglyceride levels more than any other statin.^{1,2}

RANGE



to treat more profiles and more patients than any other statin.³

SIMPLICITY



to bring 70-90% of patients to their EAS treatment goals with the 10mg once daily starting dose.⁴

...never before seen in statin therapy.

New
Lipitor[®]
atorvastatin


The most effective cholesterol lowering agent.

Abbreviated prescribing information: Lipitor[®]

Presentation: Lipitor is supplied as film coated tablets containing 10, 20 or 40mg of atorvastatin. **Indications:** In patients unresponsive to diet and other non-pharmacological measures, Lipitor is indicated for the reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in patients with primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia. Lipitor is also indicated for the reduction of elevated total cholesterol, LDL-cholesterol, and apolipoprotein B in patients with homozygous familial hypercholesterolaemia. **Dosage:** The usual starting dose is one Lipitor 10mg tablet daily. Doses may be given at any time of the day with or without food. The maximum daily dose is 80mg. **Contraindications:** Hypersensitivity to any of the ingredients, active liver disease, unexplained elevations in serum transaminases, pregnancy and breast feeding and in women of child-bearing potential not using contraception. **Warning and precautions:** Liver function tests should be performed before initiation and periodically thereafter and in patients who show signs and symptoms of liver injury (monitor raised transaminases until they return to normal). Drug dosage should be reduced or therapy discontinued if persistent elevations occur above 3-times the upper limit of normal. Lipitor should be used with caution in patients with a history of liver disease and/or alcoholism. Uncomplicated myalgias have been reported. Patients with signs and symptoms of myopathy should have their creatine phosphokinase (CPK) levels monitored. Lipitor should be discontinued if CPK levels are markedly or persistently raised or myopathy is diagnosed or suspected. Rhabdomyolysis with renal dysfunction secondary to myoglobinuria has been reported with other drugs of this class. **Pregnancy and lactation:** Lipitor is contraindicated in pregnancy and

lactation. **Interactions:** There is an increased risk of myopathy if Lipitor is used concurrently with: cyclosporin, fibric acid derivatives, erythromycin, azole antifungals and niacin. Serum levels of enzyme inhibitors such as immunomodulators, many antiarrhythmic agents, some calcium channel blockers and some benzodiazepines may be raised or lowered (erythromycin may increase levels of Lipitor). The effect of enzyme inducers (eg rifampicin or phenytoin) on Lipitor is unknown. Digoxin levels can be increased by Lipitor. Patients on warfarin should be closely monitored as Lipitor caused a minimal decrease in clotting time. Colestipol was seen to lower levels of Lipitor and norethisterone and ethyl oestradiol levels were raised in patients taking the oral contraceptive. **Side effects:** Side effects most frequently reported in controlled clinical studies: constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, asthenia, diarrhoea, insomnia, elevations in ALT and CPK levels. Other side effects have been reported in clinical trials but were not necessarily associated with the product. See Summary of Product Characteristics. **Legal category:** POM. **Date of Revision:** December 1996. **Package quantities, marketing authorisation numbers and basic NHS price:** Lipitor 10mg (28 tablets), MA0018/0240 £18.88, Lipitor 20mg (28 tablets), MA0018/0241 £30.60, Lipitor 40mg (28 tablets) MA0018/0242 £47.04. **Marketing Authorisation Holder:** Parke-Davis & Company, Usk Road, Pontypool, NP4 0YH. Lipitor is a registered trade mark. Further information is available on request from: Parke-Davis, Lambert Court, Chestnut Avenue, Eastleigh, Hampshire SO53 3ZQ. **References:** 1. Bracs P, et al. Abstract, 66th Congress of the European Atherosclerosis Society, July 1996 + Data on file, Parke-Davis RR-720-03598. 2. Egros F, et al. Abstract, 66th Congress of the European Atherosclerosis Society, July 1996 + Data on file, Parke-Davis RR-720-03594. 3. Summary of Product Characteristics. 4. Data on file, Parke-Davis. **Date of preparation:** December 1996. **Item code Z596/90036A**
LIPITOR HOTLINE: 0645 68 69 70

ABC OF ATRIAL FIBRILLATION



Edited by
Gregory Y H Lip

BMJ
Publishing Group

ABC of Atrial Fibrillation

Gregory Y H Lip

Atrial fibrillation is the commonest sustained cardiac arrhythmia, yet there is widespread misconception among the medical profession as to how it should be managed. This unique book:

- Provides a practical update on the assessment and treatment of patients with this condition
- Covers management of atrial fibrillation in both hospital and general practice
- Contains contributions from leading workers in cardiology, vascular diseases, and general practice and is edited by Gregory Lip, who has a special interest in the field
- Includes superb illustrations, with colour photographs, tables, diagrams, and line drawings

ISBN 0 7279 1070 1 48 pages 1996

UK £10.95; Overseas £12.95

(BMA members £9.95; £12.00)

BMJ
Publishing Group

Order Form

Available from: **BMJ Publishing Group, P.O. Box 295, London WC1H 9TE,**
medical booksellers or the **BMJ Bookshop in BMA House**
Tel: 0171 383 6185/6245 Fax: 0171 383 6662

Please send me _____ copy/ies of **Cheque enclosed** (made payable to
ABC of Atrial Fibrillation British Medical Journal) £ _____

Name _____ Debit my _____
American Express/Visa/Mastercard

Address _____ Card No _____


Expiry Date _____

Postcode _____

Membership No. _____ Signature _____

IOMERON Prescribing Information Presentation: Sterile, aqueous solution of iomeprol. Iomeron 150 contains 30.62% w/v (150mg I/ml); Iomeron 200 contains 40.82% w/v (200mg I/ml); Iomeron 250 contains 51.03% w/v (250mg I/ml); Iomeron 300 contains 61.24% w/v (300mg I/ml); Iomeron 350 contains 71.44% w/v (350mg I/ml); Iomeron 400 contains 81.65% w/v (400mg I/ml). **Uses:** X-ray contrast medium **Dosage and Administration:** Angiography Iomeron 250, 300, 350, 400, dosage according to procedure* DSA intra-arterial: Iomeron 150, 200, 250, 300 DSA intravenous Iomeron 250, 300, 350, 400, dosage according to procedure; CT brain Iomeron 150, 200, 250, 300, 350 50-150ml* CT body Iomeron 150, 200, 250, 300, 350, 400 40-150ml*; Urography intravenous Iomeron 250, 300, 350, 400 50-150ml* Urography infusion Iomeron 150 250ml; Arthrography Iomeron 200, 300, 350 1-10ml ECRP Iomeron 300 12-30ml; Hysterosalpingography Iomeron 200 8-20ml Elderly – lowest effective dose *Children according to body size and age **Contra-indications:** Hypersensitivity to iodine; hysterosalpingography in pregnancy or acute inflammatory pelvic conditions **Precautions and Warnings:** May provoke anaphylaxis (appropriate resuscitative measures to be available). Care in patients with history of allergy, severe asthma, functional impairment of liver, kidneys or myocardium, myelomatosis, epilepsy, diabetes, pulmonary hypertension, hyperthyroidism, acute and chronic alcoholism. Increased risk of reaction in severe cardiac disease. In severe, chronic hypertension the risk of renal damage is increased. Abnormalities of fluid and electrolyte balance should be corrected. Ensure adequate hydration. Possibility of ventricular arrhythmias during cardiac procedures and interference with thyroid function tests. Increased risk of transient neurological complications in patients with cerebrovascular disease. In pheochromocytoma, premedication with an alpha blocker is advised. Anticonvulsant therapy should not be discontinued. Some neurological symptoms may be exacerbated. Non-ionic contrast media have less anticoagulant activity *in vitro* than ionic media, so particular attention must be paid to angiographic technique. Avoid in pregnancy. **Side Effects:** As for similar non-ionic products **Pharmaceutical Precautions:** Protect from light and secondary X-rays. Containers are not for multiple use. Not to be mixed with other drugs **Legal Category:** Prescription only medicine **MA Numbers:** Iomeron 150 PL 11648/0005 PA 54/80/3; Iomeron 200 PL 11648/0006 PA 54/81/2; Iomeron 250 PL 11648/0007 PA 54/82/2,5; Iomeron 300 PL 11648/0008 PA 54/83/4, 5, 6, 8; Iomeron 350 PL 11648/0009 PA 54/84/3, 4, 5, 7; Iomeron 400 PL 11648/0010 PA 54/85/2, 3, 4, 6, 7 **Prices:** Iomeron 300 10x50mls £255.26 Full prescribing information is available on request from E Merck Pharmaceuticals (A division of Merck Ltd), Harrier House, High Street, West Drayton, Middlesex UB7 7QG. **Date of preparation:** 31 October 1995 **References:** 1. Gallotti A *et al.* Eur J Radiol 18 (Suppl.1): S1-S12, 1994. 2. Morisetti A *et al.* Eur J Radiol 18 (Suppl.): S21-S31, 1994.

MERCK 



Every picture tells a story

The new nonionic, with
low osmolality, low viscosity¹ and
low toxicity² for confidence in achieving
high patient acceptability

iomeron[®] ▼
iomeprol



Health care: the way ahead

Controversies in Health Care Policies: Challenges to Practice

Edited by Marshall Marinker

Can health policy ever be completely right?

This book explores how to get it right in six of today's most important issues: rational prescribing; primary care following Tomlinson; public access to medical information; the meaning of aging; medical practice variation; and risk in medicine.

CONTROVERSIES in HEALTH CARE POLICIES *Challenges to Practice*

EDITED BY
MARSHALL MARINKER

BMJ
Publishing Group

- Essential reading for all involved in making and implementing health care policies.

- Documents the work of six think tanks of clinical experts, GPs, managers, and patient representatives

- Includes input from the Kings Fund, NAHAT, Age Concern, RCGP, National Medical Adviser Support Centre, Social Market Foundation

- Offers innovative and realistic ideas for the way forward

ISBN 0 7279 0894 4 144 pages
November 1994
UK £12.95; Overseas £15.00
(BMA members £11.95; £14.00)

Outcomes into Clinical Practice

Edited by Tony Delamothe

Why do outcomes research?
How should it be done?

These crucial questions are addressed in this ground breaking book, based on the conference held by the BMJ, BMA, and UK Clearing House for Information on the Assessment of Health Outcomes. In it, experts in the field cover a wide range of topics including acute care; cost effectiveness; death rates; health gains; and general practice.


- Shows how information on outcomes can be used to improve care

- Gives examples of outcomes research at its best

- Looks at the subject from all perspectives in the health service

- Provides an ideal starting point for all members of clinical teams, both in hospitals and general practice, and is invaluable for health care purchasers and clinical audit officers.

ISBN 0 7279 0888 X 184 pages
November 1994
UK £17.95; Overseas £20.00
(BMA members £16.95; £19.00)



Also available

A Manual for Assessing Health Practices and Designing Practice Policies: the explicit approach

By David M Eddy

Published by the American College of Physicians

ISBN 0 943126 18 5 100 pages 1992 UK £19.95; Overseas £21.00 (BMA members £17.95; £19.00)

ORDER FORM

Available from: BMJ Publishing Group, P.O. Box 295, London WC1H 9TE (Tel: 0171 383 6185/6245),
medical booksellers or the BMJ bookshop in BMA House

Please send me the following books

Name _____
(Print Clearly)

Address _____

Postcode _____

BMA Membership No. _____


Cheque enclosed (made payable to British Medical Journal) £ _____
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No. _____ Exp _____

Signature _____

☐ Please send me a BMJ PUBLISHING GROUP CATALOGUE

BMJ
Publishing
Group



THE CHOICE FOR QUALITY WORLDWIDE

With a reputation built on consistently high quality standards, Swann-Morton Ltd is a leading manufacturer of surgical blades and scalpels to the world's surgeons.

Additional to the company's comprehensive surgical ranges are the 'Major' Orthopaedic range, the 'Fine' range, 'Minor' disposable scalpels, and specialised blades such as myringotomy and cervical biopsy. All ranges are subject to constant product development in

response to customer demand. All appropriate products are sterilised by Swann-Morton (Services) Ltd.

As well as achieving BS5750, subsequently updated to BS EN ISO 9001, Swann-Morton have now been accredited to EN 46001, which enables them to CE mark their products under the Medical Device Directive (93/42/EEC).

Swann-Morton
PRECISION IN YOUR HANDS

Swann-Morton Limited,
Owlerton Green,
Sheffield S6 2BJ, England.
Tel: 0114 234 4231
Fax: 0114 231 4966




BS EN ISO 9001 1994
Certificate No. FM 44/13



EN 46001 SP

Applying science to health care



Scientific Basis of Health Services

Edited by
Michael Peckham
and Richard Smith

BMJ
PUBLISHING GROUP

ISBN 0 7279 1029 9 200 pages April 1996
UK £22.95; Overseas £25.00
(BMA members £20.95; £23.00)

Evidence based medicine is the buzz word in health care today but the concept that the design and function of health services should also be based on scientific evidence is less familiar and more radical. Grown out of a ground breaking conference, *The Scientific Basis of Health Services* examines how the activities of health services can be rooted in research.

Chapters include:

- Economic evaluation and clinical practice
- The role of the consumer in health research
- Evidence based management in health care
- Shifting the balance between primary and secondary care

With contributions from leading international figures, this unique book points the way to the future and is essential reading for all involved in the design and management of health services.

Available from: BMJ Publishing Group, PO Box 295, London WC1H 9TE,
medical booksellers or the BMJ bookshop in BMA House.
OR: Phone on our credit card hotline: 0171 383 6185/6245 or fax: 0171 383 6662
PRINT CLEARLY Please send me.....copy/ies of *Scientific Basis of Health Services*

Name

Address

Postcode.....Membership No:

Cheque enclosed (made payable to British Medical Journal)
Debit my AMERICAN EXPRESS/MASTERCARD

Card No

Expires

Signature

BMJ
Publishing
Group

Order your copy today

Low strength


elantan[®]

isosorbide mononitrate

LA25

P

Suitable for new
and elderly
angina
patients



elantan[®] LA50

P

isosorbide mononitrate

Long term angina protection

(isosorbide mononitrate)

Presentation: Elantan LA25: Brown and white opaque gelatin capsules containing 25 mg isosorbide mononitrate in a slow release formulation. **Elantan LA50:** Brown and flesh coloured opaque gelatin capsules containing 50 mg isosorbide mononitrate in a slow release formulation. **Use:** Prophylaxis of angina pectoris. **Dosage and administration:** *Adults and Elderly:* Elantan LA25: One capsule in the morning. This may be increased to two capsules taken simultaneously if required. Elantan LA50: One capsule in the morning. This may be increased to two capsules if required. *Children:* Safety and efficacy has not been established in children. The capsules should be swallowed whole. **Contra-indications, warnings, etc.** *Contra-indications:* Acute myocardial infarction with low filling pressures, acute circulatory failure, (shock, vascular collapse), severe cerebrovascular insufficiency or very low blood pressure, known sensitivity to nitrates, marked anaemia, head trauma, cerebral haemorrhage, severe hypotension, hypovolaemia. *Interactions:* Some of the effects of alcohol and the action of hypotensive agents may be potentiated by this treatment. *Pregnancy and lactation:* Elantan LA25 and LA50 is not recommended for use during pregnancy or lactation. **Warnings:** Use with caution in patients predisposed to hypothyroidism, hypothermia, malnutrition, severe liver or renal disease. Circulatory col-

lapse may arise after the first dose. A headache may occur at the start of treatment, usually this subsides after a few days. Symptoms of postural hypotension and syncope may result in some patients. **Overdosage:** May lead to vascular collapse, gastric lavage is indicated in severe cases. Further measures to support the circulation are recommended, e.g. elevate the foot of the bed and/or treat with hypertensive agents. **Pharmaceutical precautions:** None. **Legal category:** UK: P, ROI: POM. **Package quantity and price:** Elantan LA25 Original pack of 28 capsules UK £7.00, EIRE IR£7.07, Elantan LA50 Original pack of 28 capsules UK £11.30, EIRE IR £12.15. **Marketing authorisation numbers:** Elantan LA25: PL 4438/0028 PA 271/1/9, Elantan LA50: PL 4438/0015 PA 271/1/3. **Name and address of marketing authorisation holder:** Schwarz Pharma Limited, East Street, Chesham, Bucks. HP5 1DG. Telephone: 01494 772071. **Distributed in Republic of Ireland by:** Allphar Services Ltd., Burton Hall Park, Sandyford Industrial Estate, Foxrock, Dublin 18. Telephone Dublin 2952226. **Date of preparation:** August 1996 (167).

SCHWARZ
P H A R M A